FarEye Launches Grow – A Game-changing Self-Serve Merchant Portal for Logistics Companies to Accelerate Customer Acquisition and Drive Growth
11.5.2023 17:00:00 EEST | Business Wire | Press release
FarEye today announced Grow, a solution for logistic companies to provide a modern-age experience to its customers. With a user-friendly interface, frictionless onboarding, automated booking, and seamless payments integration, Grow is set to empower logistics businesses to accelerate customer acquisition, improve customer satisfaction, and drive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005538/en/
Grow is a cutting-edge self-serve merchant portal designed to revolutionize the way logistics companies manage their shipping operations. (Photo: Business Wire)
With the parcel delivery market projected to hit $200 billion by 2026 and over tens of millions of shippers worldwide, it's clear that logistic companies have an unprecedented opportunity for growth. Every retailer and e-commerce company wants to offer home delivery but continues to struggle to find the right, modern-age logistics partner and are stuck with legacy ways of home delivery. Grow enables logistics companies to address this demand-supply gap.
"We are thrilled to launch Grow, which we believe will become an indispensable tool for logistics companies seeking to acquire new retailers and stay ahead of the competition," said Kushal Nahata, CEO of FarEye. "Our team has worked tirelessly to create a platform that unlocks the potential of thousands of logistic companies, and we are confident that Grow will transform the way logistics businesses interact with their customers and manage their day-to-day operations."
FarEye Grow is an easy way for merchants to self-serve, get quotes, create orders, generate labels, and manage transactions. It also offers shipment-level visibility and in-built exception management, enabling retailers and shippers to save time and effort, leading to increased customer satisfaction. In addition, automated invoice generation and payments with digital wallet capabilities allow logistic companies to reduce payment delays and improve cash flow. Grow is equipped with built-in plug-ins with major e-commerce platforms like Shopify and BigCommerce, allowing shippers to connect and start delivering quickly.
FarEye Grow is a part of the FarEye product portfolio that supports companies through the complete order-to-door delivery journey. It has products like Ship, Track, Route, Execute, Experience, Analyze, and now, Grow, which offers the following key benefits:
- Personalized portal for easy onboarding: Allows self-onboarding and complete order entry, get quotes, generate labels, real-time status updates, and proof of delivery on one platform.
- Track and trace visibility: Provides real-time track and trace visibility and address validation to merchants for booked orders.
- Scale with your merchants: Track merchants’ growth, run campaigns based on orders and transactions, and make recommendations for merchants to transact more for revenue and business growth.
- Booking order transparency: Self-service merchant order booking directly from the platform, this helps CEPs track revenue and reduce lost revenue.
- Digital wallet management: Offer customers purchase credit for their shipping needs. Provide complete visibility into all transactions, book and pay for shipments by multiple payment modes, including directly by wallet.
FarEye's Grow is the ultimate customer portal for CEP companies looking to streamline shipping operations, expand their customer network, and achieve sustainable growth in today's competitive industry. To learn more about the portal and how it can benefit your business, visit the FarEye website today.
About FarEye
FarEye’s Delivery Management platform turns deliveries into a competitive advantage. Retail, e-commerce and third-party logistics companies use FarEye’s unique combination of orchestration, real-time visibility, and branded customer experiences to simplify complex last-mile delivery logistics. The FarEye platform allows businesses to increase consumer loyalty and satisfaction, reduce costs and improve operational efficiencies. FarEye has 150+ customers across 30 countries and five offices globally. FarEye, First Choice for Last Mile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005538/en/
Contact information
PR Contact:
Bradford Peirce, Industry Strategy Executive, bradford.peirce@fareye.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom